Connect Biopharma reports FY2024 net loss $15.6M; cash $93.7M into 2027

Connect Biopharma Holdings Ltd

2025-Q1 EPS reported -$0.19 vs consensus -$1.92 ▲ beat (+90.1%)

Revenue $26.0M from Simcere license; no revenue in FY2023.
R&D expense $29.3M (-$23.7M YoY) as Phase 2b asthma/atopic dermatitis trials completed.
Net loss $15.6M ($0.28 EPS) vs $62.1M ($1.13) in FY2023.
Phase 2 trials of rademikibart for acute asthma/COPD start Q2 2025; data expected H2 2026.
CEO Barry Quart leads U.S.-centric shift; HQ relocated to San Diego, transition to domestic filer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.